Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

0.6203 +0.0144 (+2.38%)
Streaming Delayed Price Updated: 3:08 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
32 Stocks Moving In Friday's Mid-Day Session
Gainers CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Sykes Enterprises,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows. Noteables: The largest company in terms of market cap to set a new 52-week low was China Life Insurance Co... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings
Following the market opening Friday, the Dow traded down 1.25% to 33,401.59 while the NASDAQ fell 0.54% to 14,085.56. The S&P also fell, dropping 0.86% to 4,185.44. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving in Friday's Pre-Market Session
Gainers CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Geron... 
Via Benzinga
Athira Pharma Stock Plummets After CEO Placed On Temporary Leave
Athira Pharma Inc (NASDAQ: ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from doctoral research Dr.... 
Via Benzinga
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.